Skip to main content
. 2020 Nov 18;11:558731. doi: 10.3389/fphar.2020.558731

Table 2.

Potential biomarkers identification.

No. m/z Compound Chemical Formula Adducts HMDB ID Trend*
1 524.370 Platelet-activating factor C26H54NO7P M+H HMDB0062195
2 496.338 LysoPC(16:0) C24H50NO7P M+H HMDB0010382
3 520.337 LysoPC(18:2) C26H50NO7P M+H HMDB0010386
4 522.354 LysoPC(18:1) C26H52NO7P M+H HMDB0002815
5 550.385 LysoPC(20:1) C28H56NO7P M+H HMDB10391
6 544.340 LysoPC(20:4) C28H50NO7P M+H HMDB10395
7 835.528 PI(18:0/16:2) C43H79O13P M+H HMDB09807
8 613.393 Cholestane-3,7,12,25-tetrol-3-glucuronide C33H56O10 M+H HMDB10355
9 782.570 PC(18:3/18:1) C44H80NO8P M+H HMDB0008170
10 806.571 PC(22:5/16:1) C46H80NO8P M+H HMDB0008660
11 810.601 PC(20:4/18:0) C46H84NO8P M+H HMDB0008464
13 806.561 Lactosylceramide (d18:1/12:0) C42H79NO13 M+H HMDB04866
14 313.155 Phenylalanylphenylalanine C18H20N2O3 M+H HMDB13302

*The trend was psoriasis groups compared to healthy control group.

Fourteen significant difference metabolites were screened out to be the potential biomarkers according to the value of variable importance for projection (VIP) value in PLS-DA model.